Recent therapeutic expansion has been driven in part by accelerated regulatory pathways relying on surrogate endpoints. While these advances provide important access, long-term efficacy, and safety data remain limited. Future progress will likely require rigorous clinical outcomes and rational combination of multimodal treatment strategies.
Wilson et al. (Mon,) studied this question.